TNF-α Inhibitors and Other Biologic Agents for the Treatment of Immune Checkpoint Inhibitor-Induced Myocarditis
With anti-PD-1 antibodies serving as a representative drug, immune checkpoint inhibitors (ICIs) have become the main drugs used to treat many advanced malignant tumors. However, immune-related adverse events (irAEs), which might involve multiple organ disorders, should not be ignored. ICI-induced my...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-07-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2022.922782/full |
| _version_ | 1818218171306344448 |
|---|---|
| author | Xiaohang Liu Wei Wu Ligang Fang Yingxian Liu Wei Chen |
| author_facet | Xiaohang Liu Wei Wu Ligang Fang Yingxian Liu Wei Chen |
| author_sort | Xiaohang Liu |
| collection | DOAJ |
| description | With anti-PD-1 antibodies serving as a representative drug, immune checkpoint inhibitors (ICIs) have become the main drugs used to treat many advanced malignant tumors. However, immune-related adverse events (irAEs), which might involve multiple organ disorders, should not be ignored. ICI-induced myocarditis is an uncommon but life-threatening irAE. Glucocorticoids are the first choice of treatment for patients with ICI-induced myocarditis, but high proportions of steroid-refractory and steroid-resistant cases persist. According to present guidelines, tumor necrosis factor alpha (TNF-α) inhibitors are recommended for patients who fail to respond to steroid therapy and suffer from severe cardiac toxicity, although evidence-based studies are lacking. On the other hand, TNF-α inhibitors are contraindicated in patients with moderate-to-severe heart failure. This review summarizes real-world data from TNF-α inhibitors and other biologic agents for ICI-induced myocarditis to provide more evidence of the efficacy and safety of TNF-α inhibitors and other biologic agents. |
| first_indexed | 2024-12-12T07:19:31Z |
| format | Article |
| id | doaj.art-406a1e61586d458db33c3c4b7c16ca5f |
| institution | Directory Open Access Journal |
| issn | 1664-3224 |
| language | English |
| last_indexed | 2024-12-12T07:19:31Z |
| publishDate | 2022-07-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj.art-406a1e61586d458db33c3c4b7c16ca5f2022-12-22T00:33:24ZengFrontiers Media S.A.Frontiers in Immunology1664-32242022-07-011310.3389/fimmu.2022.922782922782TNF-α Inhibitors and Other Biologic Agents for the Treatment of Immune Checkpoint Inhibitor-Induced MyocarditisXiaohang LiuWei WuLigang FangYingxian LiuWei ChenWith anti-PD-1 antibodies serving as a representative drug, immune checkpoint inhibitors (ICIs) have become the main drugs used to treat many advanced malignant tumors. However, immune-related adverse events (irAEs), which might involve multiple organ disorders, should not be ignored. ICI-induced myocarditis is an uncommon but life-threatening irAE. Glucocorticoids are the first choice of treatment for patients with ICI-induced myocarditis, but high proportions of steroid-refractory and steroid-resistant cases persist. According to present guidelines, tumor necrosis factor alpha (TNF-α) inhibitors are recommended for patients who fail to respond to steroid therapy and suffer from severe cardiac toxicity, although evidence-based studies are lacking. On the other hand, TNF-α inhibitors are contraindicated in patients with moderate-to-severe heart failure. This review summarizes real-world data from TNF-α inhibitors and other biologic agents for ICI-induced myocarditis to provide more evidence of the efficacy and safety of TNF-α inhibitors and other biologic agents.https://www.frontiersin.org/articles/10.3389/fimmu.2022.922782/fullcardio-oncologyimmune-related adverse eventsICI-induced myocarditisbiologic agentsTNF-alpha inhibitor |
| spellingShingle | Xiaohang Liu Wei Wu Ligang Fang Yingxian Liu Wei Chen TNF-α Inhibitors and Other Biologic Agents for the Treatment of Immune Checkpoint Inhibitor-Induced Myocarditis Frontiers in Immunology cardio-oncology immune-related adverse events ICI-induced myocarditis biologic agents TNF-alpha inhibitor |
| title | TNF-α Inhibitors and Other Biologic Agents for the Treatment of Immune Checkpoint Inhibitor-Induced Myocarditis |
| title_full | TNF-α Inhibitors and Other Biologic Agents for the Treatment of Immune Checkpoint Inhibitor-Induced Myocarditis |
| title_fullStr | TNF-α Inhibitors and Other Biologic Agents for the Treatment of Immune Checkpoint Inhibitor-Induced Myocarditis |
| title_full_unstemmed | TNF-α Inhibitors and Other Biologic Agents for the Treatment of Immune Checkpoint Inhibitor-Induced Myocarditis |
| title_short | TNF-α Inhibitors and Other Biologic Agents for the Treatment of Immune Checkpoint Inhibitor-Induced Myocarditis |
| title_sort | tnf α inhibitors and other biologic agents for the treatment of immune checkpoint inhibitor induced myocarditis |
| topic | cardio-oncology immune-related adverse events ICI-induced myocarditis biologic agents TNF-alpha inhibitor |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2022.922782/full |
| work_keys_str_mv | AT xiaohangliu tnfainhibitorsandotherbiologicagentsforthetreatmentofimmunecheckpointinhibitorinducedmyocarditis AT weiwu tnfainhibitorsandotherbiologicagentsforthetreatmentofimmunecheckpointinhibitorinducedmyocarditis AT ligangfang tnfainhibitorsandotherbiologicagentsforthetreatmentofimmunecheckpointinhibitorinducedmyocarditis AT yingxianliu tnfainhibitorsandotherbiologicagentsforthetreatmentofimmunecheckpointinhibitorinducedmyocarditis AT weichen tnfainhibitorsandotherbiologicagentsforthetreatmentofimmunecheckpointinhibitorinducedmyocarditis |